Skip to main content

Innate immunity in bovine tuberculosis

Bovine tuberculosis remains the most costly agricultural problem in the UK, with this year an estimated £40m spent on testing and compensation to farmers, as well as risks of transmission to wildlife and humans. Currently, there is no effective vaccine or prophylaxis in use to combat the transmission of the disease. New interventions are needed urgently.

The objective of this project is to identify the role of soluble innate immune factors e.g. conglutinin, in the early stages of bovine tuberculosis infection and how this interaction at the host-pathogen interface contributes to the adaptive immune response against the pathogen Mycobacterium bovis and the formation of the granuloma.

The granuloma is the primary pathological feature of bovine tuberculosis in the lungs and understanding how its formed and the intricacies of the host-pathogen interface within it are essential in understanding the pathogenesis of bovine tuberculosis and how it can be combated.

We hypothesise that conglutinin and other innate immune factors could play a major role here and this may lead to new ideas for the prevention and treatment of bovine tuberculosis.

View on YouTube

Please accept all cookies to view this content. Alternatively view the content on YouTube

Publications


Meet the Principal Investigator(s) for the project

Dr Anthony Tsolaki
Dr Anthony Tsolaki - Qualifications: DPhil, University of Oxford, 1999 MSc, London School of Hygiene and Tropical Medicine, 1994 BSc (Hons), Biochemistry, University of North London, 1993   Academic Appointments September 2006 - Present Lecturer, Brunel University London September 2004 - August 2006, Post Doctoral Fellow, Imperial College London May 2000 - July 2004 Post Doctoral Fellow, Stanford University May 1999 - May 2000 University of California, Berkeley 

Related Research Group(s)

human body

Inflammation Research and Translational Medicine - Driving scientific innovation and discovery for diagnosis, treatment, and management of cardiovascular disease, inflammatory and immune disorders, microbial resistance, and cancer.


Partnering with confidence

Organisations interested in our research can partner with us with confidence backed by an external and independent benchmark: The Knowledge Exchange Framework. Read more.


Project last modified 08/07/2021